Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

971 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.
Wada T, Hibino M, Aono H, Kyoda S, Iwadate Y, Shishido E, Ikeda K, Kinoshita N, Matsuda Y, Otani S, Kameda R, Matoba K, Nonaka M, Maeda M, Kumagai Y, Ako J, Shichiri M, Naoki K, Katagiri M, Takaso M, Iwamura M, Katayama K, Miyatsuka T, Orihashi Y, Yamaoka K; CORVETTE-01 Study Group. Wada T, et al. Among authors: yamaoka k. Front Med (Lausanne). 2023 May 22;10:1139046. doi: 10.3389/fmed.2023.1139046. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37283627 Free PMC article.
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gómez-Reino JJ. Curtis JR, et al. Among authors: yamaoka k. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5. Ann Rheum Dis. 2023. PMID: 36600185 Free PMC article. Clinical Trial.
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, Palac H, Dilley D, Liu J, Strengholt S, Burmester G. Fleischmann R, et al. Among authors: yamaoka k. Ann Rheum Dis. 2023 Sep;82(9):1130-1141. doi: 10.1136/ard-2023-223916. Epub 2023 Jun 12. Ann Rheum Dis. 2023. PMID: 37308218 Free PMC article. Clinical Trial.
Optimal timing of recombinant herpes zoster virus vaccination for a JAK inhibitor treatment in rheumatoid arthritis: a multicentre, open-label, randomised comparative study (STOP-HZ study): study protocol.
Takanashi S, Ohmura K, Misaki K, Ihata A, Matsui T, Tohma S, Saegusa J, Sato S, Matsubara T, Yamaoka K, Amano K, Miyamoto T, Mori Y, Kaneko Y. Takanashi S, et al. Among authors: yamaoka k. BMJ Open. 2024 Nov 17;14(11):e090668. doi: 10.1136/bmjopen-2024-090668. BMJ Open. 2024. PMID: 39551586 Free PMC article.
971 results